Table 3 Changes in laboratory parameters in MGUS and SMM patients over time.
From: Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
MGUS to MGUS (n = 49) | MGUS to MM (n = 42) | SMM to MM (n = 29) | p value | |
|---|---|---|---|---|
Sample 1 | ||||
Months between diagnosis and collection | 0 (0, 0) | 0.3 (0–61) | 0.7 (0, 3.15) | <0.001 |
MCP - g/dL | 0 (0, 0.7) | 1.1 (0, 1.8) | 2.3 (1.8, 2.75) | <0.001 |
iFLC, - mg/dL | 2.4 (1.8, 4.5) | 4.6 (2.1, 11.9) | 6.3 (2.4, 18.6) | 0.025 |
dFLC - mg/dL | 0.8 (0.4, 2.7) | 4.4 (1.5, 12.6) | 6.0 (3.2, 18.3) | <0.001 |
sBCMA - ng/mL | 41.9 (24.1, 79.6) | 106.5 (78.9, 227.3) | 174.9 (84.3, 347.1) | <0.001 |
Months between collection of samples 1 and 2 | 20.8 (15.8, 37.8) | 36.7 (24.4, 51.1) | 22.1 (16.0, 32.2) | 0.001 |
Absolute change over time | ||||
MCP - g/dL | 0 (0, 0) | 2.1 (0.9, 2.9) | 1.1 (0.7, 1.7) | <0.001 |
iFLC, - mg/dL | −0.2 (−0.6, 0.6) | 18.4 (3.1, 71.3) | 2.3 (0.3, 24.5) | <0.001 |
dFLC - mg/dL | −0.05 (−0.39, 0.56) | 15.8 (4.1, 73.0) | 2.1 (0.4, 24.5) | <0.001 |
sBCMA - ng/mL | 2.7 (−9.4, 18.1) | 311.6 (150.1, 774.5) | 302.8 (57.7, 656.5) | <0.001 |
Fold change over time | ||||
MCP - g/dL | 0 (−0.3, 2.8) | 1.8 (0.8, 599) | 0.3 (0.6) | <0.001 |
iFLC, - mg/dL | −0.1 (−0.2, 0.3) | 4.2 (0.8, 7.4) | 0.6 (0.1, 2.5) | <0.001 |
dFLC - mg/dL | −0.01 (−0.5, 0.8) | 4.9 (1.2, 13.8) | 0.7 (0.1, 3.3) | <0.001 |
sBCMA - ng/mL | 0.1 (−0.2, 0.5) | 2.7 (0.9, 7.4) | 1.2 (0.7, 2.9) | <0.001 |
